Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Idhifa is a prescription isocitrate dehydrogenase 2 inhibitor containing enasidenib. It is indicated for adults with relapsed or refractory acute myeloid leukemia that has an IDH2 mutation detected by an FDA-approved test. Tablets are available in 50 mg and 100 mg strengths.
read more about idhifa ...Enasidenib inhibits mutant IDH2 enzymes, including R140Q, R172S, and R172K. This decreases production of the abnormal metabolite 2-hydroxyglutarate and promotes differentiation of myeloid cells. Patient selection is based on detection of an IDH2 mutation in blood or bone marrow.
Idhifa is used in adults with relapsed or refractory acute myeloid leukemia and an IDH2 mutation confirmed by an FDA-approved test. Blood counts and blood chemistries are checked before treatment and at least every two weeks during the first three months to detect leukocytosis, tumor lysis syndrome, and other abnormalities.
The recommended dose is 100 mg by mouth once daily with or without food until disease progression or unacceptable toxicity. In patients without progression or unacceptable toxicity, treatment continues for at least six months to give time for clinical response. Tablets are swallowed whole and are not chewed, split, or crushed.
Idhifa carries a boxed warning for differentiation syndrome, which can be fatal without treatment. Suspected differentiation syndrome is treated promptly with corticosteroids and hemodynamic monitoring. Other concerns include leukocytosis, tumor lysis syndrome, elevated bilirubin, drug interactions, and fetal harm.
Idhifa treats relapsed or refractory acute myeloid leukemia with an IDH2 mutation in adults.
An FDA-approved test is used to detect an IDH2 mutation in blood or bone marrow.
The recommended dose is 100 mg once daily with or without food.
Yes. The boxed warning concerns differentiation syndrome, which can become fatal without prompt treatment.
DailyMed - IDHIFA - enasidenib mesylate tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5b4cdf0-3fa8-4c6c-80f6-8d8a00e3a5b6. Date Accessed October 2, 2026.
Enasidenib - MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a617040.html. Date Accessed October 2, 2026.
Enasidenib Mesylate - National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/enasidenibmesylate. Date Accessed October 2, 2026.
FDA Approves New Targeted Treatment for Relapsed or Refractory Acute Myeloid Leukemia. https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-relapsed-or-refractory-acute-myeloid-leukemia. Date Accessed October 2, 2026.
List of FDA-Authorized Companion Diagnostic Devices. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools. Date Accessed October 2, 2026.